Real-world efficacy and safety of trastuzumab emtansine biosimilar (UJVIRA(®)) in early and metastatic HER2-positive breast cancer: a multicenter pooled retrospective analysis from India.

Mahajan A, Panda SS, Moharana L, Chandrakanth MV, Agarwala V, Manna R, Saju SV, Raju SH, Ganesan P, Shankar G, Phillip AO, Cyriac SL, Jose A, Unnikrishnan P, Bhatia KP, Sehrawat A, Sundriyal D, Dhanai H, Samantaray L, Mohanty SS, Dubashi B

Open source

DOI: 10.1007/s10549-026-08114-0
Published: 2026 Oct 28
Container: Breast cancer research and treatment
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s10549-026-08114-0,
  title = {Real-world efficacy and safety of trastuzumab emtansine biosimilar (UJVIRA(®)) in early and metastatic HER2-positive breast cancer: a multicenter pooled retrospective analysis from India.},
  author = {Mahajan A and Panda SS and Moharana L and Chandrakanth MV and Agarwala V and Manna R and Saju SV and Raju SH and Ganesan P and Shankar G and Phillip AO and Cyriac SL and Jose A and Unnikrishnan P and Bhatia KP and Sehrawat A and Sundriyal D and Dhanai H and Samantaray L and Mohanty SS and Dubashi B},
  year = {2026},
  journal = {Breast cancer research and treatment},
  doi = {10.1007/s10549-026-08114-0},
  url = {https://doi.org/10.1007/s10549-026-08114-0}
}

RIS

TY  - JOUR
TI  - Real-world efficacy and safety of trastuzumab emtansine biosimilar (UJVIRA(®)) in early and metastatic HER2-positive breast cancer: a multicenter pooled retrospective analysis from India.
AU  - Mahajan A
AU  - Panda SS
AU  - Moharana L
AU  - Chandrakanth MV
AU  - Agarwala V
AU  - Manna R
AU  - Saju SV
AU  - Raju SH
AU  - Ganesan P
AU  - Shankar G
AU  - Phillip AO
AU  - Cyriac SL
AU  - Jose A
AU  - Unnikrishnan P
AU  - Bhatia KP
AU  - Sehrawat A
AU  - Sundriyal D
AU  - Dhanai H
AU  - Samantaray L
AU  - Mohanty SS
AU  - Dubashi B
PY  - 2026
JO  - Breast cancer research and treatment
DO  - 10.1007/s10549-026-08114-0
UR  - https://doi.org/10.1007/s10549-026-08114-0
ER  -

APA

A, M., SS, P., L, M., MV, C., V, A., R, M., SV, S., SH, R., P, G., G, S., AO, P., SL, C., A, J., P, U., KP, B., A, S., D, S., H, D., L, S., SS, M., & B, D. (2026). Real-world efficacy and safety of trastuzumab emtansine biosimilar (UJVIRA(®)) in early and metastatic HER2-positive breast cancer: a multicenter pooled retrospective analysis from India.. Breast cancer research and treatment. https://doi.org/10.1007/s10549-026-08114-0

Source records

pubmed · retrieved 2026-11-10T11:41:10.323Z
europe-pmc · retrieved 2026-11-10T11:41:10.335Z